Medesis Pharma Financials
| ALMDP Stock | EUR 0.43 0.01 2.38% |
Medesis |
Understanding current and past Medesis Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Medesis Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Medesis Pharma's assets may result in an increase in income on the income statement.
Medesis Pharma Stock Summary
Medesis Pharma competes with Biophytis, Gensight Biologics, OSE Pharma, and Abivax SA. Medesis Pharma SA, a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. The company was founded in 2003 and is based in Montpellier, France. MEDESIS PHARMA is traded on Paris Stock Exchange in France.| Instrument | France Stock View All |
| Exchange | Euronext Paris |
| ISIN | FR0010844464 |
| Business Address | LOre des Mas, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.medesispharma.com |
| Phone | 33 4 67 03 03 96 |
| Currency | EUR - Euro |
You should never invest in Medesis Pharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Medesis Stock, because this is throwing your money away. Analyzing the key information contained in Medesis Pharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Medesis Pharma Key Financial Ratios
Medesis Pharma's financial ratios allow both analysts and investors to convert raw data from Medesis Pharma's financial statements into concise, actionable information that can be used to evaluate the performance of Medesis Pharma over time and compare it to other companies across industries.Medesis Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Medesis Pharma's current stock value. Our valuation model uses many indicators to compare Medesis Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Medesis Pharma competition to find correlations between indicators driving Medesis Pharma's intrinsic value. More Info.Medesis Pharma SA is the top company in current valuation category among its peers. It also is number one stock in shares outstanding category among its peers creating about 0.51 of Shares Outstanding per Current Valuation. The ratio of Current Valuation to Shares Outstanding for Medesis Pharma SA is roughly 1.98 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Medesis Pharma's earnings, one of the primary drivers of an investment's value.Medesis Pharma SA Systematic Risk
Medesis Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Medesis Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Medesis Pharma SA correlated with the market. If Beta is less than 0 Medesis Pharma generally moves in the opposite direction as compared to the market. If Medesis Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Medesis Pharma SA is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Medesis Pharma is generally in the same direction as the market. If Beta > 1 Medesis Pharma moves generally in the same direction as, but more than the movement of the benchmark.
Medesis Pharma November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Medesis Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Medesis Pharma SA. We use our internally-developed statistical techniques to arrive at the intrinsic value of Medesis Pharma SA based on widely used predictive technical indicators. In general, we focus on analyzing Medesis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Medesis Pharma's daily price indicators and compare them against related drivers.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 75.63 | |||
| Value At Risk | (16.19) | |||
| Potential Upside | 16.22 |
Additional Tools for Medesis Stock Analysis
When running Medesis Pharma's price analysis, check to measure Medesis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medesis Pharma is operating at the current time. Most of Medesis Pharma's value examination focuses on studying past and present price action to predict the probability of Medesis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medesis Pharma's price. Additionally, you may evaluate how the addition of Medesis Pharma to your portfolios can decrease your overall portfolio volatility.